These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 2308978)

  • 41. [Ex-vivo treatment of a bone marrow graft].
    Bieva CJ
    Rev Med Brux; 1992 May; 13(5):177-82. PubMed ID: 1609193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
    Heit W; Bunjes D; Wiesneth M; Schmeiser T; Arnold R; Hale G; Waldmann H; Heimpel H
    Br J Haematol; 1986 Nov; 64(3):479-86. PubMed ID: 3539172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate.
    Bunjes D; Hertenstein B; Wiesneth M; Stefanic M; Novotny J; Duncker C; Heit W; Arnold R; Heimpel H
    Bone Marrow Transplant; 1995 Apr; 15(4):563-8. PubMed ID: 7655382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
    Hale G; Cobbold S; Waldmann H
    Transplantation; 1988 Apr; 45(4):753-9. PubMed ID: 3282358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of in vitro T lymphocyte depletion on generation of IL2-activated cytotoxic cells.
    Morecki S; Nabet C; Ackerstein A; Schlesinger M; Slavin S
    Bone Marrow Transplant; 1991 Apr; 7(4):269-73. PubMed ID: 2070132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
    Novitzky N; Thomas V; Hale G; Waldmann H
    Cytotherapy; 2004; 6(2):172-81. PubMed ID: 15203994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T-cell depletion and allogeneic bone marrow transplantation.
    O'Reilly RJ
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):20-6. PubMed ID: 1615341
    [No Abstract]   [Full Text] [Related]  

  • 50. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
    Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
    Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
    [No Abstract]   [Full Text] [Related]  

  • 51. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D
    BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.
    Mitsuyasu RT; Champlin RE; Gale RP; Ho WG; Lenarsky C; Winston D; Selch M; Elashoff R; Giorgi JV; Wells J
    Ann Intern Med; 1986 Jul; 105(1):20-6. PubMed ID: 3521427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of graft-versus-host disease in HLA-matched bone marrow transplantation for malignant diseases: a multicentric study of 62 patients using 3-pan-T monoclonal antibodies and rabbit complement.
    Racadot E; Hervé P; Beaujean F; Vernant JP; Flesch M; Plouvier E; Andreu G; Rio B; Philippe N; Souillet G
    J Clin Oncol; 1987 Mar; 5(3):426-35. PubMed ID: 3546617
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1996 Mar; 17(3):305-8. PubMed ID: 8704678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.
    Hale G; Bright S; Chumbley G; Hoang T; Metcalf D; Munro AJ; Waldmann H
    Blood; 1983 Oct; 62(4):873-82. PubMed ID: 6349718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Severe migratory polyarthritis following in vivo CAMPATH-1G.
    Varadi G; Or R; Rund D; Orbach H; Slavin S; Nagler A
    Bone Marrow Transplant; 1995 Dec; 16(6):843-5. PubMed ID: 8750280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
    Klangsinsirikul P; Carter GI; Byrne JL; Hale G; Russell NH
    Blood; 2002 Apr; 99(7):2586-91. PubMed ID: 11895797
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
    Chakrabarti S; Hale G; Waldmann H
    Transplant Proc; 2004 Jun; 36(5):1225-7. PubMed ID: 15251298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Graft versus host disease prophylaxis today.
    Martelli MF; Aversa F
    Bone Marrow Transplant; 1991; 7 Suppl 2():112-6. PubMed ID: 1908726
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.